That makes sense for p2 trials, not p3;
there are large gaps between test completion and full readout because Anavex is both conducting clinical trials and wide-ranging, groundbreaking scientific research.
Remember for alz we had a p2a trial that was supposed to work all that out, with the P2b/3 trial for confirmation of efficacy and dose.
Ditto for PD, that was a fishing expedition so of course a long time to analyze is reasonable.
But the current alz results are targeted, and should not take that long.
At least throw us a bone and put out the 50mg top line results.